Sign Out
Madopar is indicated in the treatment of Parkinson's disease.
Madopar dispersible is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.
Madopar HBS is indicated for patients presenting with all types of fluctuations (e.g. "peak-dose dyskinesia" and "end of dose deterioration" - such as nocturnal immobility).
